[1]
Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med 2019; 17(1): 90. Published 2019
May 9.
[http://dx.doi.org/10.1186/s12916-019-1326-5]
[http://dx.doi.org/10.1186/s12916-019-1326-5]
[2]
Wein L, Luen SJ, Savas P, Salgado R, Loi S. Checkpoint blockade in the treatment of breast cancer: current status and future directions. Br J Cancer 2018; 119(1): 4-11.
[http://dx.doi.org/10.1038/s41416-018-0126-6]
[http://dx.doi.org/10.1038/s41416-018-0126-6]
[3]
Mittica G, Ghisoni E, Giannone G, et al. PARP Inhibitors in Ovarian Cancer. Recent Pat Anticancer Drug Discov 2018; 13(4): 392-410.
[http://dx.doi.org/10.2174/1574892813666180305165256]
[http://dx.doi.org/10.2174/1574892813666180305165256]
[4]
El Bairi K, Amrani M, Kandhro AH, Afqir S. Prediction of therapy response in ovarian cancer: Where are we now? Crit Rev Clin Lab Sci 2017; 54(4): 233-66.
[http://dx.doi.org/10.1080/10408363.2017.1313190]
[http://dx.doi.org/10.1080/10408363.2017.1313190]
[5]
Le Page C, Chung J, Rahimi K, Kobel M, Provencher D, Mes-Masson AM. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. [published online ahead of print, 2019 Oct 16]. Curr Drug Targets 2019.
[http://dx.doi.org/10.2174/1389450120666191016143836]
[http://dx.doi.org/10.2174/1389450120666191016143836]
[6]
Lengyel CG, Altuna SC, Habeeb BS, Trapani D, Khan SZ. The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas. [published online ahead of print, 2019 Nov 20] Curr Drug Targets 2019.
[http://dx.doi.org/10.2174/1389450120666191120123612]
[http://dx.doi.org/10.2174/1389450120666191120123612]
[7]
Tazzite A, Jouhadi H, Benider A, Nadifi S. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. [published online ahead of print, 2020 Feb 3] Curr Drug Targets 2020.
[http://dx.doi.org/10.2174/1389450121666200203162541]
[http://dx.doi.org/10.2174/1389450121666200203162541]
[8]
Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K. Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response. [published online ahead of print, 2020 Jan 28]. Curr Drug Targets 2020.
[http://dx.doi.org/10.2174/1389450121666200128161733]
[http://dx.doi.org/10.2174/1389450121666200128161733]
[9]
Gouri A, Benarba B, Dekaken A, Aoures H, Benharkat S. Prediction of late recurrence and distant metastasis in early-stage breast cancer: Overview of Current and Emerging Biomarkers. [published online ahead of print, 2020 Mar 11] Curr Drug Targets 2020.
[http://dx.doi.org/10.2174/1389450121666200312105908]
[http://dx.doi.org/10.2174/1389450121666200312105908]
[10]
El Bairi K, Afqir S, Amrani M. Is HE4 superior over CA-125 in the follow-up of patients with epithelial ovarian cancer? [published online ahead of print, 2020 Apr 25]. Curr Drug Targets 2020.
[http://dx.doi.org/10.2174/1389450121666200425211732]
[http://dx.doi.org/10.2174/1389450121666200425211732]
Article Metrics
4